Ultragenyx Pharmaceutical (RARE) Stock Highlights

57.7 | -1.35%

2024-09-19 00:51:40

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The companys medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Statistics

Range Today

57.44 58.95

Volume Today 484.25K

Range 1 Year

31.52 60.37

Volume 1 Year 211.28M

Range 3 Year

31.52 99.79

Volume 3 Year 506.31M

Range 10 Year

31.52 179.647

Volume 10 Year 1.4B

Highlights

Market Capitalization 5.41B (mid)

Floating Shares 88.85M

Current Price 57.7

Price To Earnings -8.04

Price To Revenue 11.58

Price To Book 12.51

Earnings Per Share -7.21

Payout Ratio 0%

Performance

Latest -1.35%

1 Month +8.77%

3 Months +45.38%

6 Months +20.36%

1 Year +53.66%

3 Years -39.8%

5 Years +30.54%

10 Years +2.32%

Benchmarks

Market Capitalization

37 / 368

Gross Profits

274 / 278

Total Revenue

28 / 300

Total Rank

46 / 368

Free Cashflow

343 / 352

Performance 5 years

109 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.